Viewing nowSitagliptin Hydrochloride Hydrate 100 mg (Sitagliptin)
Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea Union Pharmaceutical Co., Ltd.

MFDS item code 202100087 · Approved 2021.01.06 · Insurance code 665508330
Improvement of glycemic control in patients with type 2 diabetes mellitus
This drug is used in conjunction with diet and exercise to help control blood sugar levels in patients with type 2 diabetes. It can be administered alone for patients needing initial treatment, and if blood glucose control is insufficient with monotherapy, it can be combined with other diabetes medications such as metformin. Additionally, if blood glucose control is difficult even with monotherapy with sulfonylurea, thiazolidinediones, or insulin or other combination therapies, this medication can be added to enhance blood sugar control. It is used to effectively improve patients' blood sugar levels.
Administer 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, section 5. General Precautions). Patients with renal impairment Because dosage adjustment based on renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.
This medication may cause severe allergic reactions after administration; therefore, if symptoms such as skin rash or difficulty breathing occur, use should be discontinued immediately and medical attention sought. During the course of treatment, severe pancreatitis may occur, so if symptoms such as abdominal pain or vomiting appear, consult a doctor immediately. This medication should not be used by patients with type 1 diabetes or diabetic ketoacidosis, nor should anyone with an allergy to this drug or its components take it. Patients with impaired kidney function should have their dosage adjusted; therefore, treatment should be conducted under a doctor's direction, and regular kidney function tests are important. This medication may cause hypoglycemia; thus, when taken with insulin or sulfonylurea, carefully monitor for hypoglycemic symptoms and adjust the dosage of other medications as necessary. Additionally, severe joint pain or skin blisters may appear during the treatment, and if such symptoms arise, they should be reported to medical personnel immediately. Pregnant or breastfeeding women are advised to avoid using this medication, and safety has not been established for children and adolescents under 18. Elderly patients may have reduced kidney function, so kidney function should be assessed before taking this medication, and periodic checks during treatment are necessary. In the case of overdose, standard treatment should be initiated, and if necessary, some of the medication may be removed via dialysis. Drug interactions are generally low; however, when taking certain medications, consultation with a doctor is recommended, especially when taking digoxin, as blood concentrations should be carefully monitored.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to prevent air exposure, at room temperature between 1 degree and 30 degrees Celsius. This will help maintain the drug's efficacy for a longer time.
Light orange round biconvex film-coated tablet
30 tablets/box [(10 tablets/PTP×3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea Union Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.